1-6 of 6
Kenneth F. Bradstock, MBBS
Close
Sort by
Journal Articles

Improved Concordance of Minimal Residual Disease Measurements By Quantitative PCR and 10-Color Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia

Mary Sartor, PhD, Draga Barbaric, MBBS, Tamara Law, BSc (Hons), DR Anuruddhika Dissanayake, PhD, Nicola C Venn, Mawar Karsa, BSc (Hons), MSc, Sue W J Wong, BSc, MSc(MD, Murray D Norris, PhD, Tamas Revesz, MD PhD, Petra Ritchie, MBBS, Peter J Shaw, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, Luciano Dalla Pozza, MBBS, FRACP, Toby N Trahair, PhD MBBS, Rosemary Sutton, PhD
Journal: Blood
Blood (2015) 126 (23): 2614.
https://doi.org/10.1182/blood.V126.23.2614.2614
Published: 2015
Journal Articles

Alterations in the Cell Cycle of Acute Lymphoblastic Leukemia Cells Resistant to Everolimus

Jordan Basnett, BSc(Hons), Eve Diefenbach, PhD, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, Linda J. Bendall, BSc, PhD
Journal: Blood
Blood (2014) 124 (21): 3640.
https://doi.org/10.1182/blood.V124.21.3640.3640
Published: 2014
Journal Articles

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Harry J Iland, MBBS FRACP FRCPA, Marnie Collins, BCom BSc(Hons), Mark S Hertzberg, MBBS PhDFRACP FRCPA, Michael Seldon, MBBS FRACP FRCPA, Andrew P Grigg, MBBS FRACP FRCPA MD, Frank Firkin, MBBS PhDFRACP FRCPA, Shane G Supple, BSc(Hons) PhD, Lynda J Campbell, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, John F Seymour, MBBS, FRACP, PhD
Journal: Blood
Blood (2014) 124 (21): 375.
https://doi.org/10.1182/blood.V124.21.375.375
Published: 2014
Journal Articles

Evaluation Of Sphingosine Kinase 1 As a Therapeutic Target In B-Lineage Acute Lymphoblastic Leukemia

Craig T Wallington-Beddoe, BSc, MBBS, PhD, FRACP, FRCPA, Stuart M Pitson, BAppSc, PhD, Jason A Powell, BSc, PhD, Kenneth F Bradstock, MBBS, PhD, FRACP, FRCPA, Linda J Bendall, BSc, PhD
Journal: Blood
Blood (2013) 122 (21): 1426.
https://doi.org/10.1182/blood.V122.21.1426.1426
Published: 2013
Journal Articles

Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Angela Smiley, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Andrew W. Roberts, MBBS, PhD, Kenneth F Bradstock, MBBS, PhD, FRACP, FRCPA, Richard De Abreu Lourenco, Andrew Spencer, MD
Journal: Blood
Blood (2013) 122 (21): 537.
https://doi.org/10.1182/blood.V122.21.537.537
Published: 2013
Journal Articles

First Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) Trial of Thalidomide and Alternate Day Prednisolone Following Autologous Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (ALLG MM6).

Andrew Spencer, MBBS, Miles Prince, MBBS, Andrew W. Roberts, MBBS, Kenneth F. Bradstock, MBBS, Ian W. Prosser, MBBS
Journal: Blood
Blood (2006) 108 (11): 58.
https://doi.org/10.1182/blood.V108.11.58.58
Published: 2006